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Objective: To determine whether either of two magnetic resonance imaging approaches e delayed
gadolinium enhanced magnetic resonance imaging of cartilage (dGEMRIC), or T2 mapping e can detect
short-term changes in knee hyaline cartilage among individuals taking a formulation of collagen
hydrolysate.
Design: Single center, prospective, randomized, placebo-controlled, double-blind, pilot trial of collagen
hydrolysate for mild knee osteoarthritis (OA). Participants were allowed to continue the prior analgesic
use. The primary outcome was change in dGEMRIC T1 relaxation time in the cartilage regions of interest
at the 24-week timepoint. Secondary endpoints included the change in dGEMRIC T1 relaxation time
between baseline and 48 weeks, the change in T2 relaxation time at 0, 24 and 48 weeks, the symptom
and functional measures obtained at each of the visits, and overall analgesic use.
Results: Among a sample of 30 randomized subjects the dGEMRIC score increased in the medial and
lateral tibial regions of interest (median increase of 29 and 41 ms respectively) in participants assigned to
collagen hydrolysate but decreased (median decline 37 and 36 ms respectively) in the placebo arm with
the changes between the two groups at 24 weeks reaching signiﬁcance. No other signiﬁcant changes
between the two groups were seen in the other four regions, or in any of the T2 values or in the clinical
outcomes.
Conclusions: These preliminary results suggest that the dGEMRIC technique may be able to detect change
in proteoglycan content in knee cartilage among individuals taking collagen hydrolysate after 24 weeks.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Given the scale of the public health impact of osteoarthritis (OA),
it is remarkable that it beneﬁts from few, if any, disease-modifying
medical remedies. Although a number of factors may have obfus-
cated the testing of effective interventions for OA, the absence of
a useful biomarker of articular health has been a primary obstacle
to drug development. However, the recent application of: T.E. McAlindon, Division of
ch, Tufts Medical Center, Box
d States.
g (T.E. McAlindon).
s Research Society International. Psophisticated imaging technology to evaluate structural change in
osteoarthritic joints offers an opportunity to measure pathological
progression in critical structures such as articular cartilage. Two
magnetic resonance imaging (MRI)-based approaches for which
the preliminary data indicate such potential include delayed
gadolinium enhanced MRI of cartilage (dGEMRIC)1 and T2
mapping2.
dGEMRIC exploits the tendency of the negatively-charged
contrast agent Gd-DTPA2 to accumulate in hyaline cartilage in
concentrations that correlate inversely with its proteoglycan
content1. Ex-vivo studies have shown a strong correlation of the
dGEMRIC index with quantitative measures of proteoglycan
content and with semi-quantitative histologic scores3. A lower
dGEMRIC index has been associated with regions of hyalineublished by Elsevier Ltd. All rights reserved.
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patients with hip dysplasia syndrome5. The technique appears to
discriminate between knees subjected to different levels of physical
activity, both cross-sectionally6 and longitudinally7. The T2 relax-
ation time, on the other hand, reﬂects the water content of cartilage
tissue and correlates with age and symptomatic degeneration,
albeit with qualitative differences in the nature of T2 increases
attributable to age vs degeneration8. The parameter also appears to
be immediately sensitive to change following exercise and rest9.
Since changes in proteoglycan and water distribution and content
are features of early OA, these techniques have the potential to
operate as proxy indicators of the state of cartilage health.
Leveraging these properties could allow efﬁcacy testing of putative
structure-modifying interventions for OA at an early stage of
disease development. However, this possibility has not yet been
tested.
As a product promulgated for beneﬁts on cartilage health,
collagen hydrolysate (CH) is representative of many putative OA
interventions whose development and clinical validation would be
greatly facilitated by the availability of an objective measure of
articular cartilage health. CH is a nutritional product derived from
animal collagenous tissues comprising a range of polypeptides with
molecular weights from 3 to 10 kDa. CH induces the novel synthesis
of type 2 collagen and proteoglycans in the extracellular matrix in
a dose-dependent manner10, is readily absorbed across the gastro-
intestinal mucosa in murine models and distributes to hyaline
cartilage, where it accumulates11. In the STR/ort mouse model of
spontaneous OA, oral administration of CH reduced both the
development and progression of cartilage damage12,13. A range of
clinical reports and observations suggest that CH may beneﬁt
symptoms of OA, with one randomized clinical trial producing
mixed results14.
Since our knowledge of both the measurement properties of
these imaging techniques, and the in-vivo efﬁcacy of CH, is insuf-
ﬁcient to design a deﬁnitive clinical trial, we performed a pilot
study to determine if dGEMRIC and T2 mapping can discriminate
changes in knee hyaline cartilage among participants taking a CH
preparation (Fortigel) compared to those taking placebo.
Methods
Overview
The study was designed as a single center, prospective,
randomized, placebo-controlled, double-blind, pilot trial with
a planned enrollment of 30 participants with mild knee OA, testing
the ability of dGEMRIC and T2 mapping to detect change in carti-
lage attributable to CH. The primary endpoint occurred at 24weeks,
with the possibility of a further 24-week extension contingent on
a blinded interim analysis by a data and safety monitoring board.
The study was approved by the Institutional Review Boards of
Tufts e New England Medical Center (protocol #7598) and Beth
Israel Deaconess Medical Center (protocol #2006-P-000151). It was
conducted at Tufts e New England Medical Center under an FDA
investigational new drug registration (IND #74249), and registered
on the ClinicalTrials.gov website (identiﬁer NCT00536302).
Sample
We recruited individuals aged 49 years or older with mild to
moderate severity knee OA, based on an afﬁrmative response to
a standard knee pain question “during the past 6 months, have you
had any pain in the knee more than half the days of the month?”,
a Western Ontario and McMaster Universities (WOMAC) osteoar-
thritis index pain subscale score greater than one, and at least onedeﬁnite osteophyte on postero-anterior, weight-bearing, semi-
ﬂexed or lateral knee radiographs. In order to constrain the sample
to those with milder disease, we required that their radiographs
demonstrate relative preservation of tibiofemoral joint space
(>3 mm). By deﬁnition, these criteria are consistent with the
American College of Rheumatology classiﬁcation system for knee
OA15. Other eligibility criteria included that participants be prepared,
during the course of the study, to refrain from use of agents
purported to have effects on articular cartilage (such as glucosamine
and chondroitin) and maintain a stable analgesic regimen. We
excluded applicants who reported taking agents purported to have
chondroprotective effects (such as glucosamine and chondroitin)
within 14 weeks, used opioids on a chronic basis, were expecting to
have knee arthroscopy or arthroplasty, had any contraindications to
undergoing MRI or receiving intravenous gadolinium, had active
pathology that could confound interpretation of knee pain or any
conditions that could interfere with adherence.
Study intervention
The CH formulation employed in this study (Fortigel) was
a liquid that comprised 10 g of CH, 0.4 g fructose, malt extract, citric
acid, xanthan, potassium sorbate, acesulfame-K, sucralose and
natural and artiﬁcial ﬂavors in 10 ml water. The placebo, which was
identical in appearance and ﬂavor, contained the identical excipi-
ents but no CH.
Randomization and blinding
Participants were randomized on a 1:1 basis to receive either CH
or placebo using a computer-generated blocked randomization list,
stratiﬁed by body mass index around a cut-point of 32 kg/m2. The
randomization list was generated by Dr Imma Fischer, biomathe-
matician at the Institute for Medical Information Processing, the
University of Tuebingen in Germany. The randomization list was
retained by the sponsor, Gelita AG. The active and placebo formu-
lations were provided in identical ampoules by Gelita AG. They
were shipped to the Tufts e New England Medical Center research
pharmacy, whose staff stored them in preparation for dispensation.
The research pharmacy dispensed the study medication to partic-
ipants in an 8-week supply.
Concomitant analgesic use
During the trial we permitted participants to continue taking
their regular analgesics or nonsteroidal anti-inﬂammatory drugs.
We encouraged them to maintain a ﬁxed regimen when taking
these medications during the course of the trial and required that
they account for all consumption of such medications prospec-
tively, on a paper calendar supplied by the study team.
Study assessments
Study evaluations comprised a screening visit and a baseline
assessment (week 0) followed by scheduled visits at weeks 8, 16,
24, 32, 40, and 48, with a window of 7 days around each study
evaluation timepoint.
MRI protocol
dGEMRIC and T2 MRI scans were acquired at baseline, 24 and
48 weeks. Patients were injected with 0.2 mmoles/kg Gd-DTPA2
(Magnevist, Berlex, NJ) and asked to walk for 10 min to aid in the
transport of the contrast agent into the tissue. 90 min post-injec-
tion dGEMRIC imaging was performed using quad knee coil on
a 1.5 T Twin Speed Excite scanner (GE Healthcare, Waukesha, WI).
Pre-screen and 
Telephone screen 
(n=181) 
Ineligible  
(n=86)
Booked screening 
appointments 
(n=95)
Eligible (n=40) 
“No Shows” (n=23) 
Screen Failures 
x-ray (n=16) 
referred knee pain (n=2) 
WOMAC (n=5) 
declined to consent (n=2)
surgery plans (n=1) 
unable to comply (n=1) 
PI exclusion (n=5)
Withdrew consent 
prior to randomization 
(n=9) 
Randomized (n=31) 
Completed protocol 
(n=29)
Drop-outs 
Claustrophobia (n=1) 
Subject replaced 
Withdrew consent after 
Week 40 (n=1) 
Fig. 1. Flow of recruitment.
Table I
Demographics and baseline characteristics of participants
CH* (n¼ 15) Placebo (n¼ 15) P*
Age, y, mean (SD) 58.9 (8.0) 60.3 (8.5) 0.65
Gender (female), n (%) 9 (60%) 9 (60%) 1.00
Race, n (%) 1.00
White 14 (93%) 13 (87%)
Asian 1 (7%) 0
Black 0 1 (7%)
American Indian 0 1 (7%)
BMI, kg/m2, mean (SD) 30.1 (4.6) 31.2 (7.0) 0.60
KL score¼ 2 (vs 1), n (%) 14 (93%) 13 (87%) 0.54
* P-values are from tests comparing the CH and placebo groups using either the
Student t-test (age, BMI), Fisher-exact test (race), or chi-square test (gender, KL).
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recovery prepared fast spoiled 3D gradient echo acquisition with
a ﬂip angle ¼20, square ﬁeld of view ¼14 cm, matrix ¼512 512,
bandwidth ¼62.5 kHz. Five inversion delays (TI¼ 1650, 650, 350,
150, 28 ms) were used with a variable repetition time between
consecutive inversion pulses (Tr) ranging from 360 ms to 1920 ms
and 7.3/3.1 ms (Ts/Te).
Multi-slice fast spin echo Fat Sat Dual Echo (Tr 3000 ms, Te
88.3 ms, Etl 6, Nex 1, Matrix 512 512) images were acquired that
covered the same section of the knee as the dGEMRIC series.
dGEMRIC and T2 mapping computational analyses
We used a software analysis package (MRIMapper, Beth Israel
Deaconess Medical Center & Massachusetts Institute of Technology,
2006) to generate cartilage maps reﬂecting the dGEMRIC T1 and the
T2 relaxation times. Three regions of interest (ROIs)were analyzed in
each of the medial and lateral sections of the knee; the central
weight-bearing medial/lateral femoral cartilage (cMF/cLF), the
posterior medial/lateral femoral cartilage (pMF/pLF) and the medial/
lateral tibial plateau cartilage (MT/LT). The dGEMRICmaps generated
inMatlabused a pixel-by-pixel three-parameter T1ﬁt. The T2 images
were used as a guide for cartilage segmentation. The dGEMRIC data
were corrected for dose bias due to the subjects’ varying body mass
indexes, aspreviouslydescribed16. ThedGEMRICvalue reported is the
average of a given ROI. T2 data were also analyzed using the same
software in the three ROIs per section. For follow-up scans, the choice
of section for analysis was visually matched to prior scans.
Clinical assessments
Screening and baseline assessments included posteri-
oreanterior semi-ﬂexed radiography according to a standardized
protocol17, a physical examination to document clinical features of
knee OA and rule out alternative causes of knee pain, and
measurement of height and weight. At each visit we assessed pain
during the prior 24 h using theWOMAC-Likert scale version 3.0 and
a global pain visual analog scale. We measured functional capacity
using both the timed 20 m walking and chair stand tests. We
documented overall concomitant analgesic consumption at each
visit aided by paper calendars provided to each participant.
Evaluation of adherence
Dosing instructions were reviewed at each study visit by study
staff. We instructed participants to return at each visit the study
ampoules that had been dispensed to them at the previous
encounter. These were collected and counted by study staff. We
evaluated adherence as the number of used ampoules returned
divided by the number of days elapsed since the last visit.
Adverse event surveillance
We instructed participants to record in their study calendar any
changes to their health or medications during the study. We asked
participants at each study visit if they had experienced any adverse
experiences since the previous encounter. Adverse events were
subjectively assessed by the principal investigator prior to
unblinding of treatment allocation. Reported adverse events were
recorded and classiﬁed according to the affected body system,
severity (including need for hospitalization), inferred relation to
investigational product (blinded), action taken, status and outcome.
Analytic plan
Our a priori primary outcome was the change in dGEMRIC T1
relaxation time in the cartilage ROIs between baseline and the24-week timepoint. Secondary endpoints included the change in
the dGEMRIC T1 relaxation time between baseline and 48 weeks,
the change in T2 relaxation time at 0, 24 and 48 weeks, the
symptom and functional measures obtained at each of the visits,
and overall analgesic use. Change was analyzed as both raw change
from baseline as the primary measures and percent change from
baseline as ancillary measures.
In order to evaluate trends in concomitant analgesic use in the
groups, we transformed consumption of these pills into a single
scale reﬂecting their relative efﬁcacy in relation to acetaminophen.
Our general approach to evaluation of all endpoints was
to test for differences between baseline and 24 weeks and
baseline and 48 weeks by using a Students two-tailed t-test
comparison of change between the two groups. However, in
the event that the distribution of the outcomes did not
conform to normality, we used non-parametric tests to compare
groups.
Table II
Baseline values for the clinical outcome measures
CH* (n¼ 15) Placebo (n¼ 15) P*
WOMAC mean score (SD)
Pain 4.6 (2.6) 5.8 (3.0) 0.24
Stiffness 2.9 (1.1) 2.8 (1.5) 0.89
Function 12.9 (8.7) 20.6 (10.9) 0.04
Total 20.3 (10.5) 29.2 (13.8) 0.06
20-m walk, mean seconds, (SD) 16.8 (2.4) 19.7 (4.4) 0.04
Chair stand mean seconds, (SD) 14.7 (3.5) 17.7 (5.9) 0.10
Analgesic consumption
Median mg, <interquartile range> 0 (0e127587) 0 (0e6153) 0.70
Any, n (%) 7 (47%) 6 (40%) 0.71
* P-values from two-sample Student t-test (clinical measures), Wilcoxon rank-
sum test (mg of analgesics) and chi-square test (any analgesics).
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Prior studies provided insights into the extent of variability we
would encounter in the dGEMRIC analyses. For example,
a comparison of OA vs non-diseased cartilage found T1 values for
non-diseased vs OA cartilage of 380 ms vs 290 ms, with standard
deviation of 80 ms4. A sample size of 15 in each group, a two-tailed
test and a signiﬁcance level of 0.05, would provide 84% power to
detect change of this magnitude. For a change of 40 ms (an effect
size of 0.5) power fell to 38%.
Results
Sample
We screened 181 applicants between April and November 2007
to reach the target enrollment goal of 30 subjects (Fig. 1). Study
participation ended 11/13/2008 per protocol. One randomized
subject withdrew because of claustrophobia in the MRI scanner.
This subject was replaced by randomizing an additional subject
thus increasing the actual number of randomized subjects to 31 inTable III
Median and mean baseline dGEMRIC index scores and 24 and 48 week change from bas
Median (25the75th percentile) Mean standard deviation
CH
Baseline (n¼ 15) 24 Weeks
(change from baseline)
(n¼ 15)
48 Weeks
(change from
(n¼ 15)
Site
Medial tibia 410.1
(333.1 to 442.6)
396.5 82.9
28.6*
(29.5 to 74.4)
29.6 70.5
47.6
(15 to 81.9)
41.4 70.9
Central medial femur 457.5
(420.2 to 496.2)
451.4 53.0
15.6
(56.2 to 60.5)
10.3 72.3
17.1
(71 to 33.3)
16.7 75.2
Posterior medial femur 475.2
(415.6 to 517.1)
465.1 61.6
27.7
(16.4 to 44.8)
13.6 57.6
15.3
(27.8 to 64.
17.5 63.0
Lateral tibia 472.3
(362.5 to 550)
455.7 90.4
40.7*
(26.6 to 75.5)
25.5 60.2
28.3
(1.6 to 75.4)
20.0 65.0
Central lateral femur 471.2
(428.6 to 495.3)
460.6 66.9
18.2
(30.5 to 103.4)
7.2 69.9
5.4
(25.3 to 31.
2.5 47.1
Posterior lateral femur 446.6
(364.4 to 477.5)
443.9 87.9
38.4
(10.2 to 65.4)
31.5 68.1
30.8
(54.6 to 55.
6.2 77.9
* Statistically signiﬁcant differences in change scores between randomization groups
(P¼ 0.02). No other statistically signiﬁcant differences (at P 0.05) level were found. The
tibia at 48weeks (P¼ 0.08) and lateral tibia at 48weeks (P¼ 0.07) were<0.10 and all othe
are from the Wilcoxon rank-sum test.order to achieve the target number of 30 enrolled and analyzable
subjects, or 15 subjects per group. Another participant withdrew
consent after the Week 40 study visit. The active and placebo
groups were reasonably matched on most demographic charac-
teristics, although there was a nonsigniﬁcant trend toward greater
body mass index in the placebo group (Table I). With respect to the
balancing of disease severity, there was some evidence for slightly
greater impairment in the group randomized to placebo (Table II).
There were no signiﬁcant differences between the active and
control in the baseline values for the dGEMRIC index scores or T2
values (Tables III and IV).
Adherence
Overall, the dosing adherence for the study was 96.2% for all
participants (range 49e100%). There was no difference in compli-
ance between the groups (96.6 vs 95.8%).
dGEMRIC
Figure 2 displays examples of dGEMRIC images manifesting
change. Since there was evidence of non-normality of distribution
of the outcome measures, we conservatively employed a Wilcoxon
rank-sum (non-parametric) test for the unadjusted analyses.
We found statistically signiﬁcant differences in change scores
between randomization groups in the medial tibia at 24 weeks
(P¼ 0.03) and lateral tibia at 24 weeks (P¼ 0.02) (Table III).
Although differences in the regions appeared to persist, the
P-values associated with the group differences in change scores at
48 weeks were P¼ 0.08 for the medial tibia and P¼ 0.07 for the
lateral tibia and thus did not meet statistical signiﬁcance. All other
group differences in change from baseline had P-values >0.10.
However, there was a fair amount of variability between regions
with apparent (nonsigniﬁcant) trends in opposing directions.
We further explored these data using percent change from
baseline and using non-parametric and parametric methods (t-testeline scores
Placebo
baseline)
Baseline
(n¼ 15)
24 Weeks
(change from baseline)
(n¼ 14)
48 Weeks
(change from baseline)
(n¼ 13)
427.6
(375.4 to 495.2)
441.8 75.6
37.4
(93.3 to 19.8)
30.0 62.6
23.3
(27.2 to 44.7)
2.4 64.4
468.2
(384.2 to 512.6)
447.3 73.4
21.6
(11.3 to 63.7)
23.5 47.0
4.7
(56.1 to 22.3)
14.3 52.1
7)
445.3
(404.4 to 534.6)
458.9 74.6
21.9
(32.5 to 64.2)
6.8 68.1
5.7
(32 to 20.2)
2.2 55.4
508
(416.3 to 562.6)
483.8 89.5
35.9
(60.3 to 18.5)
28.5 47.8
1.3
(55.7 to 21.3)
17.3 55.3
1)
461.6
(380.9 to 502.3)
448.1 72.7
30.5
(8.3 to 56.7)
31.3 60.1
3.2
(4.7 to 25.7)
15.2 43.7
7)
440
(394.2 to 477.4)
434.0 52.3
27.2
(15.8 to 70.2)
24.3 57.8
19.0
(25.1 to 93)
40.3 88.3
were found for medial tibia at 24 weeks (P¼ 0.03) and lateral tibia at 24 weeks
P-values associated with the group differences in change scores between for medial
r group differences in change from baseline had P-values>0.10. All reported P-values
Table IV
Median baseline T2 index scores and 24- and 48-week change from baseline scores
CH Placebo
Baseline 24 Weeks
(change from baseline)
48 Weeks
(change from baseline)
Baseline 24 Weeks
(change from baseline)
48 Weeks
(change from baseline)
Sample size 14 14 11 15 15 11
Medial tibia 35.5 1.0 1.0 35.0 1.0 1.0
Central medial femur 41.0 0.5 1.0 40.0 0.0 1.0
Posterior medial femur 47.5 0.5 2.0 45.0 1.0 2.0
Lateral tibia 33.0 2.0 1.0 35.0 0.0 1.0
Central lateral femur 43.5 1.5 2.0 42.0 1.0 0.0
Posterior lateral femur 46.5 1.0 1.0* 45.0 0.0 0.0
* A statistically signiﬁcant difference (P< 0.05) in change scores between randomization groups was found for the posterior lateral femur region at 48 weeks. No other
statistically signiﬁcant differences were detected. The Wilcoxon rank-sum test was used.
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different to those of the prior analyses.Secondary outcomes
When the T2 values over time were evaluated, it became
apparent that there was very little change in the ROIs (Table IV). As
with the T1 analysis, we chose to present results from the more
conservative non-parametric analysis used to compare the change
from baseline values between the two groups (although results
from the t-test were very similar, data not shown). Statistical
analysis with a Wilcoxon rank-sum test failed to show signiﬁcant
differences between the groups except at 48 weeks in the posterior
lateral femur region where it decreased (median change¼1.0,
mean change¼1.1) in the CH group and increased (median
change¼ 0, mean change¼þ1.8) in the placebo group (P¼ 0.05).
The clinical indices broadly improved in both groups without
any major differences between them, except perhaps a trendFig. 2. Example of dGEMRIC images from the (top) placebo, and (bottom) CH group. The lin
ROI. Over time, more red areas in the tibial plateau in the placebo case illustrate the decrea
illustrates an increase in the dGEMRIC index.toward greater improvement in the stiffness subdomain of the
WOMAC in the CH group (Table V). However, the groups were
imbalanced at baseline for a number of these outcomes.
There was no signiﬁcant difference in the amount of analgesic
use (median of acetaminophen equivalents) at any of the study
timepoints, nor in the total amount accumulated over the 48-week
period.Adverse events
There were 43 adverse events reports (13 participants) among
the CH group and 45 (13 participants) among the placebo group.
Only one event (appendicitis) was classiﬁed as serious and this
occurred in the CH group and was considered unrelated to treat-
ment. The relationship to treatment among the remaining
42 adverse events in the CH group was ‘unrelated’ for 39 and
‘unlikely’ for four. There were no serious adverse event reports
among the placebo group. The relationship to treatment among thees delineate the separation between the central femoral ROI and the posterior femoral
se in the dGEMRIC index, while the shift from red to yellow/green in the CH example
Table V
Change in clinical indices at 24 and 48 weeks
CH Placebo
24 Weeks 48 Weeks 24 Weeks 48 Weeks
Sample size 15 14 15 15
WOMAC
Pain 1.5 (2.8) 2.3 (2.6) 1.4 (3.5) 1.9 (4.3)
Stiffness 1.2 (0.9) 1.2 (1.5) 0.5 (1.1) 0.6 (1.4)
Function 3.4 (6.9) 3.2 (4.6) 4.7 (6.9) 7.1 (9.5)
Total 6.1 (8.9) 6.7 (6.4) 5.7 (9.8) 9.6 (14.1)
20-m walk (s) 1.3 (1.2) 1.8 (0.9) 2.1 (1.7) 2.2 (2.4)
Chair stand (s) 1.4 (2.1) 2.1 (1.9) 2.0 (2.1) 2.8 (3.5)
All reported values are (mean SD). The change in 24-weekWOMAC stiffness score
between randomization groups was of borderline statistical signiﬁcance (P¼ 0.08).
No other between-group differences were detected. The Student t-test was used.
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for 44 and ‘unlikely’ for one.
Discussion
We designed this pilot study to test of the potential of
dGEMRIC to detect a change in cartilage status in the setting of
a randomized clinical trial of CH, a developmental product tar-
geted for OA. The dGEMRIC index has been validated as a tech-
nique to indicate proteoglycan concentration within hyaline
cartilage, with seminal studies that included pathological corre-
lation1. We chose to apply dGEMRIC to test CH because this
compound is being developed speciﬁcally as an agent to promote
cartilage health. CH is absorbed following oral administration and
distributed to joints11. The compound stimulates cultured chon-
drocytes to synthesize type 2 collagen and proteoglycans10. In
other in-vivo experiments, it retarded both the development and
progression of OA lesions12. Our pre-speciﬁed primary outcome
was change in the dGEMRIC index in the medial compartments at
the 24-week timepoint.
Our results showed varying directions of change in the dGEMRIC
index among the ROIs, with signiﬁcant differences between groups
only in the medial and lateral tibial cartilage regions. In these
regions the dGEMRIC score increased among those assigned to CH
but decreased in the placebo group. Similar trends, however, were
not observed in the other cartilage ROIs. Indeed, there was
considerable variability in the dGEMRIC outcome data between the
different regions, with apparent, nonsigniﬁcant, trends in opposite
directions. Since this was a small pilot study, it is possible that these
changes might all have occurred within the range of random
effects. Alternatively, these inconsistencies could reﬂect regionally
directed beneﬁts of CH, perhaps contingent on the distribution of
extant pathology. Therefore, we view our results as an afﬁrmation
that the dGEMRIC technique, and the CH intervention, merit further
testing in a larger study. However, because of the pilot nature of this
study, and its small sample size, we do not regard these results to be
deﬁnitive.
In contrast to the dGEMRIC results, the T2 cartilage measures
showed little variability or change with time, and no differences in
any region between groups.
Also negative were our secondary clinical outcome measures,
including measures of pain and physical function. Both groups
exhibited improvement in scores, likely reﬂecting regression to the
mean. However, the participant groups were unbalanced at base-
line with respect to clinical severity, and there was substantial
variability in the clinical outcomes data, which may have limited
our ability to detect differences. Also, we allowed the participants
to continue their use of prior analgesics, which may have attenu-
ated any clinical efﬁcacy. Future studies should use an approach tomitigate this possibility, such as the use of an analgesic washout
period prior to each pain assessment.
It is pertinent that we constrained our sample to individuals
with relatively mild knee OA. The underlying reasoning was
twofold e ﬁrstly, the dGEMRIC technique requires sufﬁcient
remaining cartilage to provide reliable measurements e secondly,
we infer from the laboratory data on CH that its potential to
stimulate an effective chondrocyte response may be predicated on
the presence of intact collagenous matrix. Consequently, the results
of this study may be generalizable only to mild OA and not
necessarily to those with disease of greater severity.
Additional limitations of this study relate to its small sample size
and the absence of morphometric MRI sequences. These factors
precluded an analysis of the relationship of macroscopic cartilage
damage to the dGEMRIC and T2 measures, which are questions of
interest that could be addressed in future appropriately-designed
studies.
In conclusion, we have been able to deploy dGEMRIC in a pilot
clinical trial of a developmental product for knee OA and have
detected apparent changes in tibial cartilage proteoglycan
concentration within a 6-month observation period.Role of the funding source
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